JP2021524446A5 - - Google Patents
Info
- Publication number
- JP2021524446A5 JP2021524446A5 JP2020564462A JP2020564462A JP2021524446A5 JP 2021524446 A5 JP2021524446 A5 JP 2021524446A5 JP 2020564462 A JP2020564462 A JP 2020564462A JP 2020564462 A JP2020564462 A JP 2020564462A JP 2021524446 A5 JP2021524446 A5 JP 2021524446A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- composition according
- immunotoxin
- antigen
- antibody
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024124917A JP2024163118A (ja) | 2018-05-16 | 2024-07-31 | 免疫毒素とチェックポイント阻害剤との組み合わせを用いるネオアジュバントがん処置 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862672150P | 2018-05-16 | 2018-05-16 | |
| US62/672,150 | 2018-05-16 | ||
| US201862675263P | 2018-05-23 | 2018-05-23 | |
| US62/675,263 | 2018-05-23 | ||
| US201962844857P | 2019-05-08 | 2019-05-08 | |
| US62/844,857 | 2019-05-08 | ||
| PCT/US2019/032671 WO2019222504A1 (en) | 2018-05-16 | 2019-05-16 | Neoadjuvant cancer treatment with immunotoxin and checkpoint inhibitor combination |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024124917A Division JP2024163118A (ja) | 2018-05-16 | 2024-07-31 | 免疫毒素とチェックポイント阻害剤との組み合わせを用いるネオアジュバントがん処置 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021524446A JP2021524446A (ja) | 2021-09-13 |
| JP2021524446A5 true JP2021524446A5 (https=) | 2022-05-23 |
| JPWO2019222504A5 JPWO2019222504A5 (https=) | 2022-05-23 |
| JP7536295B2 JP7536295B2 (ja) | 2024-08-20 |
Family
ID=68540816
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564462A Active JP7536295B2 (ja) | 2018-05-16 | 2019-05-16 | 免疫毒素とチェックポイント阻害剤との組み合わせを用いるネオアジュバントがん処置 |
| JP2024124917A Abandoned JP2024163118A (ja) | 2018-05-16 | 2024-07-31 | 免疫毒素とチェックポイント阻害剤との組み合わせを用いるネオアジュバントがん処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024124917A Abandoned JP2024163118A (ja) | 2018-05-16 | 2024-07-31 | 免疫毒素とチェックポイント阻害剤との組み合わせを用いるネオアジュバントがん処置 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210214442A1 (https=) |
| EP (1) | EP3793585A4 (https=) |
| JP (2) | JP7536295B2 (https=) |
| CN (1) | CN112423778A (https=) |
| WO (1) | WO2019222504A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021087105A1 (en) | 2019-10-30 | 2021-05-06 | Duke University | Immunotherapy with combination therapy comprising an immunotoxin |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US20090269343A1 (en) * | 2008-04-11 | 2009-10-29 | Duke University | Dual Specific Immunotoxin for Brain Tumor Therapy |
| AU2015327868A1 (en) * | 2014-10-03 | 2017-04-20 | Novartis Ag | Combination therapies |
| EP3370773B1 (en) * | 2015-11-04 | 2022-01-05 | Duke University | Combination therapy of immunotoxin and checkpoint inhibitor |
| AU2017206656B2 (en) * | 2016-01-10 | 2024-02-01 | Neotx Therapeutics Ltd. | Immunopotentiator enhanced superantigen mediated cancer immunotherapy |
| WO2017214182A1 (en) * | 2016-06-07 | 2017-12-14 | The United States Of America. As Represented By The Secretary, Department Of Health & Human Services | Fully human antibody targeting pdi for cancer immunotherapy |
| EP3496707A4 (en) * | 2016-08-09 | 2020-03-25 | Angimmune, LLC | Treatment of cancer using a combination of immunomodulation and check point inhibitors |
| JP2019533718A (ja) * | 2016-09-27 | 2019-11-21 | セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． | がんの処置における使用のための組換え免疫毒素 |
| US11311628B2 (en) * | 2016-10-17 | 2022-04-26 | Duke University | Production of immunotoxin D2C7—(scdsFv)—PE38KDEL |
| WO2018156448A1 (en) * | 2017-02-21 | 2018-08-30 | The Board Of Regents Of The Uiversity Of Texas System | Prediction and treatment of immunotherapeutic toxicity |
-
2019
- 2019-05-16 JP JP2020564462A patent/JP7536295B2/ja active Active
- 2019-05-16 US US17/055,639 patent/US20210214442A1/en not_active Abandoned
- 2019-05-16 EP EP19802992.8A patent/EP3793585A4/en active Pending
- 2019-05-16 CN CN201980032281.XA patent/CN112423778A/zh active Pending
- 2019-05-16 WO PCT/US2019/032671 patent/WO2019222504A1/en not_active Ceased
-
2024
- 2024-07-31 JP JP2024124917A patent/JP2024163118A/ja not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021511058A5 (https=) | ||
| JP2021528423A5 (https=) | ||
| JP2018508483A5 (https=) | ||
| RU2018147413A (ru) | PD-L1 специфические антитела | |
| JP2017514461A5 (https=) | ||
| JP2019515008A5 (https=) | ||
| FI3932951T3 (fi) | Menetelmiä ihosyövän hoitamiseksi antamalla PD-1-inhibiittoria | |
| JP2018534933A5 (https=) | ||
| JP2009541492A5 (https=) | ||
| RU2013102225A (ru) | АНТИТЕЛА ПРОТИВ Axl И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| JP2018505177A5 (https=) | ||
| JP2017501167A5 (https=) | ||
| JP2016063817A5 (https=) | ||
| JPWO2019147831A5 (https=) | ||
| RU2018107693A (ru) | Комбинированные виды лечения и их варианты применения и способы | |
| RU2012131411A (ru) | АНТИТЕЛА ПРОТИВ Bv8 И ИХ ПРИМЕНЕНИЕ | |
| JP2024016024A5 (https=) | ||
| RU2014109093A (ru) | Антитела против нейрегулина и их применение | |
| JP2018529661A5 (https=) | ||
| JP2021506817A5 (https=) | ||
| JPWO2019246356A5 (https=) | ||
| JP2021524446A5 (https=) | ||
| FI3880186T3 (fi) | PD-1-inhibiittoreiden intralesionaalinen antaminen ihosyövän hoitamiseksi | |
| JP2016540826A5 (https=) | ||
| JP2020521798A5 (https=) |